Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. 1995

K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
First Department of Surgery, Osaka City University Medical School, Japan.

Tumour growth depends on neovascularisation and tumour cell proliferation. Factor VIII-related antigen (F-VIII RA) localises to vascular endothelium. Expression of proliferating cell nuclear antigen (PCNA) is correlated with cell proliferation. We investigated the correlation between the expression of these antigens and prognosis in gastric carcinoma. A total of 108 specimens resected from patients with gastric carcinoma were investigated by staining with monoclonal antibodies against F-VIII RA and PCNA. Microvessel count (MVC; the mean number of microvessels in the five areas of highest vascular density at 200 x magnification) and PCNA labelling index (PCNA LI; percentage of positive cells in more than 500 tumour cells) were determined. The results showed that prognosis was significantly worse in patients who had a tumour with a high MVC (16 or greater) or a high PCNA LI (42% or greater) than in those patients who had a tumour with a low MVC (less than 16) or a low PCNA LI (less than 42%). Furthermore, MVC was significantly associated with the risk of hepatic recurrence. In conclusion, both MVC and PCNA LI may be good prognostic indicators in patients with gastric carcinoma.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
January 1994, Urologia internationalis,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
January 1997, European urology,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
September 1996, The Journal of pathology,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
June 2019, Journal of cellular and molecular medicine,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
April 2023, Biochemical genetics,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
January 1996, The International journal of biological markers,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
January 2010, Actas urologicas espanolas,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
April 2013, Gut,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
January 1995, Anticancer research,
K Maeda, and Y S Chung, and S Takatsuka, and Y Ogawa, and N Onoda, and T Sawada, and Y Kato, and A Nitta, and Y Arimoto, and Y Kondo
September 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!